Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Research Article

In vitro Modified Release Studies on Melatoninergic Fluorinated Phenylalkylamides: Circumventing their Lipophilicity for Oral Administration

In Press, (this is not the final "Version of Record"). Available online 09 April, 2024
Author(s): Marilena Vlachou*, Angeliki Siamidi, Chrystalla Protopapa, Michalis Vlachos, Sofia Kloutsou, Chrysoula-Christina Dreliozi and Ioannis P. Papanastasiou
Published on: 09 April, 2024

DOI: 10.2174/0113816128304967240328065809

Abstract

Introduction: In an attempt to circumvent the lipophilicity burden for the oral administration of new potent synthetic melatoninergic fluorine-substituted methoxyphenylalkyl amides, we conducted in vitro modified release studies using carefully selected matrix tablets’ biopolymeric materials in different ratios.

Method: In particular, we sought to attain release profiles of these analogues similar to that of the parent compound, the chronobiotic hormone Melatonin (MLT), and also of the commercially available drug, Circadin®.

Result: It was found that some of these systems, albeit being more lipophilic than MLT, mimic the in vitro release patterns of melatonin and Circadin®.

Conclusion: Moreover, a number of these derivatives were proven suitable for dealing with sleep onset problems, whilst others for dealing with combined sleep onset/sleep maintenance dysfunctions

Keywords: melatonin, synthetic melatoninergic analogues, lipophilicity, matrix tablets, in vitro dissolution studies


© 2024 Bentham Science Publishers | Privacy Policy